Edit
Foamix Pharmaceuticals
http://www.foamix.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 21.10.2019
Active
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology.
Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea.
Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea.
Location: Israel, Center District, Rehovot
Employees: 51-200
Total raised: $64M
Founded date: 2003
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.07.2019 | - | $64M | OrbiMed |
Mentions in press and media 2
| Date | Title | Description |
| 21.10.2019 | FDA approval lets Foamix set its maiden acne therapy on course for US market launch | Months ago, Foamix leaned on its biggest shareholders — Perceptive Advisors and OrbiMed — to financially grease its wheels, ahead of the FDA decision date for its acne therapy. On Friday, that approval came in — and the top... |
| 30.07.2019 | Approval in sight, Perceptive, OrbiMed double down on Foamix's antibiotic foam to the tune of $64M | In anticipation of a long-awaited — and somewhat delayed — date with the FDA on its topical dermatology drugs, Foamix has returned to its biggest shareholders to stack up resources for the commercial stretch ahead. David D... |